ClinicalTrials.gg

Program

ASC30

A development code. Also written as “ASC30 tablets A1” and “ASC30 tablets”.

Its studies are mostly in Obesity · Diabetes Mellitus, Type 2, led by Ascletis Pharma.

Furthest: phase 3, since Jul 29, 20264 company-led studies, 2 open or runningNext primary completion: Jul 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ascletis Pharma42 open or runningphase 3since Jul 29, 2026Oct 30, 2024Jul 2028phase 3 · NCT07743463

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 30, 2024First study: phase 1 study in Weight ManagementFirst studyNCT06680440 · 72 enrolled · United States
  2. Jan 5, 2026Phase 2 study in Diabetes Mellitus, Type 2NCT07321678 · 100 enrolled · United States
  3. Jul 29, 20262 phase 3 studies in ObesityPhase 3 reachedNCT07743463, NCT07743450

Ahead

  1. Jul 2028Primary completion: phase 3 study in ObesityNCT07743463
  2. Jul 2028Primary completion: phase 3 study in ObesityNCT07743450

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07743463Obesity · United States, Canada, Czechia and more3RecruitingJul 20283,003
NCT07743450Obesity · United States, Czechia, Germany and more3RecruitingJul 20281,560
NCT07321678Diabetes Mellitus, Type 2 · United States2CompletedAug 10, 2026100
NCT06680440Weight Management · United States1CompletedApr 3, 202572

How it is read

Names in the registry

  • “ASC30 tablets A1”, 2 entries
  • “ASC30 tablets”, 1 entry
  • “ASC30”, 1 entry

Codes read as this program: ASC30.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.